Okogen Announces First Patient Dosed in Phase 1/2 EMERALD Trial Evaluating Treyegen for Acute Infectious Conjunctivitis
Plano, Texas--(Newsfile Corp. - November 2, 2026) - Okogen, Inc., a clinical-stage biotechnology company developing a host-directed antiviral platform, today announced that the first patient has been dosed in the EMERALD Trial, its multicenter Phase 1/2 clinical study evaluating Treyegen (OKG-0303) for acute infectious conjunctivitis. First dosing occurred at Ambade Eye Hospital in Nagpur, India. To view the full announcement, including downloadable images, bios, and more, click here. Key...
2026-11-02 10:50 AM EST
Okogen Receives CDSCO Authorization to Advance the EMERALD Phase 1/2 Study of Treyegen (OKG-0303) for Acute Infectious Conjunctivitis
Plano, Texas--(Newsfile Corp. - October 6, 2026) - Okogen, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for infectious diseases, today announced that the Central Drugs Standard Control Organisation (CDSCO), India's national drug regulatory authority, has authorized the EMERALD study, the Company's Phase 1/2 clinical trial evaluating Treyegen (OKG-0303) for the treatment of acute infectious conjunctivitis. To view the full announcement, including...
2026-10-06 9:28 AM EDT